A review of ibogaine as a possible treatment for opioid dependence

The question

Could ibogaine, a plant-derived psychoactive compound long used in West Central African ceremonies, help treat opioid dependence, and how safe is it?

What they did

The authors reviewed published work on ibogaine. They looked at how it acts in the brain, what risks have been reported, and what clinical trials have been done so far. No new patients were studied.

What they found

Ibogaine acts on many brain systems at once, including mu and kappa opioid receptors, dopamine, serotonin, NMDA and nicotinic acetylcholine receptors. The authors suggest its anti-addiction effects may come from action on nicotinic acetylcholine receptors in the ventral tegmental area of the midbrain. On safety, ibogaine has been shown to prolong the QTc interval, a measure of the heart’s electrical cycle, and this led to a dangerous heart rhythm and cardiac arrest in one reported case. In contrast, an observational study of 30 people reported no serious adverse events. A phase 1/2a trial has finished, but no adverse event results have been published.

The fine print

This is a narrative review, not a systematic review or a pooled analysis, so the selection of studies may be incomplete. The safety evidence it cites is thin: a single case of cardiac arrest and one small observational group of 30 people, with no control group. Results from the completed early-phase trial were not available. This summary is based on the abstract only.

What it means

Ibogaine remains an unproven candidate for opioid dependence. The reported heart-rhythm risk is the central safety concern, and well-controlled trials are needed before any conclusions about benefit or safety can be drawn.

Evidence grade: Very low. This is a narrative review that summarizes other work rather than reporting new data, and it gives few details about how studies were selected or assessed.

This summary is based on the study’s published abstract.